A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Tofacitinib (Primary) ; Adalimumab; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ORAL STRATEGY
- Sponsors Pfizer
Most Recent Events
- 01 Mar 2022 Results evaluating the impact of tofacitinib using posthoc analysis of phase III and phase IIIb/IV trials published in The Journal of Rheumatology
- 09 Nov 2021 Results of post hoc analyses from RCT data: Cohort C, (NCT00814307, NCT02187055); C2, (NCT01039688); and C3, (NCT00413699, NCT00661661) assessing the patient characteristics, efficacy, and treatment patterns for tofacitinib monotherapy in patient with rheumatoid arthritis using RCT data and available RWD, presented at the ACR Convergence 2021.
- 24 Aug 2021 Results of a post hoc analysis assessing the differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate published in the Arthritis Research and Therapy